Sunitinib

Sunitinib (marketed as Sutent) is a multi-targeted receptor tyrosine kinase (RTK) inhibitor used in the treatment of several types of cancer. It is also known as a small molecule inhibitor. Sunitinib is used to treat gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and pancreatic neuroendocrine tumors (PNET). It works by blocking the activity of certain proteins involved in the growth and spread of cancer cells. Sunitinib is taken orally as a capsule or tablet and is usually taken once a day.

Sunitinib, also known by the brand name Sutent, is a medication used to treat several types of cancer. Here's a breakdown of its key features:

Function:

• Sunitinib is a targeted therapy drug, classified as a receptor tyrosine kinase (RTK) inhibitor.
• RTKs are proteins on the surface of cells that play a role in cell growth and division. Cancerous cells often have abnormal RTK activity, which can fuel their uncontrolled growth.
• Sunitinib works by blocking the action of multiple RTKs, essentially interrupting these growth signals and hindering cancer cell proliferation.

Applications:

• Sunitinib is primarily used to treat:
  • Advanced renal cell carcinoma (RCC): This is kidney cancer that has spread to other parts of the body.
  • Gastrointestinal stromal tumors (GISTs): These are rare tumors that form in the digestive system. It's specifically used for GISTs that are resistant to another medication called imatinib (Gleevec) or when imatinib is not an option for the patient.
  • Pancreatic neuroendocrine tumors (pNETs): These are slow-growing tumors arising from hormone-producing cells in the pancreas. Sunitinib is used for pNETs that have progressed and cannot be surgically removed.
  • In some cases, Sunitinib may also be used to help prevent the recurrence of RCC after surgical removal of a kidney.

Dosage and administration:

• Sunitinib comes in tablet form and is typically taken orally once a day on a specific schedule with cycles on and off the medication.